At Epi One, we’re on a mission to change the landscape of cancer detection. Our recent webinar, led by our CEO, Michael Marquardt, highlighted our commitment to developing early, accurate, and affordable cancer testing. Here’s a recap of our journey and vision.

You can catch the entire replay here. 

A Personal Mission Born from Loss

Our CEO’s dedication to this cause stems from a deeply personal experience. Michael shared, “My life took a tragic turn soon after I arrived in the United States. When my first wife died of cancer, kidney cancer, very tragically, I was only 30 years old.” This profound loss has fueled our company’s CEO to improve cancer care and detection and become a lead investor in Epi One.

The Science Behind Our Approach

At the core of our technology is a novel approach to cancer detection. As Michael explained, “When a cell in the human body turns cancerous, it essentially leaves behind fingerprints in bodily fluids. Whether that’s blood, it might be urine, it might be tissue fluid, and these fingerprints are detectable if you know what you’re looking for.”

Our epigenetics-based testing platform aims to identify these biomarkers with high accuracy, potentially years before conventional methods can detect cancer.

Making a Global Impact

We believe our technology has the potential to transform cancer care worldwide. Our goals include:

• Detecting cancer at stage one, potentially years earlier than current methods
• Achieving sensitivity and specificity rates in the 90th percentile for some cancers
• Offering tests for under $500, making widespread screening more accessible
• Extending our reach to developing countries and underserved communities

As Michael emphasized, “We’re looking to make this available to people that are currently not even able to get other kind of preventative screening, again especially outside the United States and some of the domestic areas that are more disadvantaged.”

Join Us in Our Mission

As we move towards commercialization, with plans to offer laboratory-developed tests by early 2025, we’re inviting investors to be part of our journey. Michael stated, “We’re raising capital from the crowd to build a broad base of investors. We have almost 300 investors at this point. And we’re building really real public excitement.”

We believe in the power of early detection. As Michael put it, “About the only thing you want to hear after you get a cancer diagnosis is that we caught it early.” Our mission is to make this reassurance a reality for more patients worldwide.

If you’re inspired by our vision to transform cancer care, we invite you to consider becoming part of the Epi One story. As Michael said, “We want everyone to be a part of epi one… help us transform cancer diagnosis around the world to save lives.”

To learn more about investing in Epi One and joining our mission to improve cancer detection worldwide, visit our equity crowdfunding page on Start Engine.

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.